Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Catalent, Inc. (CTLT)
since 2015 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Catalent, Inc..
Table 2 shows the detailed insider transactions.
This company's CIK number is 1596783.
Total stock buying since 2015: $5,376,345.
Total stock sales since 2015: $2,137,153,103.
Total stock option exercises since 2015: $62,473,161.
Table 3. Detailed insider trading at Catalent, Inc. (CTLT)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2024-11-11 | Ryan Michelle R (Director) | Sale | 2,800 | 59.70 | 167,160 |
| 2024-10-18 | Ferraro Joseph Anthony (SVP, General Counsel, CCO) | Sale | 320 | 59.97 | 19,190 |
| 2024-09-26 | Mcerlane David (Group President, Biologics) | Sale | 1,994 | 59.97 | 119,580 |
| 2024-08-02 | Hopson Ricky (Pres. BioProduct Delivery, CoS) | Sale | 662 | 59.56 | 39,428 |
| 2024-08-02 | Ferraro Joseph Anthony (SVP, General Counsel, CCO) | Sale | 608 | 59.58 | 36,224 |
| 2024-08-02 | Gunther Scott (SVP, Quality & Reg. Affairs) | Sale | 666 | 59.55 | 39,660 |
| 2024-08-02 | Evoli Lisa (SVP, Chief HR Officer) | Sale | 3,859 | 59.67 | 230,266 |
| 2024-08-02 | Gennadios Aristippos (Group Pres. Pharma & Consumer) | Sale | 1,169 | 59.55 | 69,613 |
| 2024-07-29 | Hopson Ricky (Pres. BioProduct Delivery, CoS) | Sale | 206 | 58.67 | 12,086 |
| 2024-07-29 | Gunther Scott (SVP, Quality & Reg. Affairs) | Sale | 283 | 58.69 | 16,609 |
| 2024-07-29 | Maselli Alessandro (President & CEO) | Sale | 9,088 | 58.76 | 534,010 |
| 2024-07-29 | Gennadios Aristippos (Group Pres. Pharma & Consumer) | Sale | 349 | 58.70 | 20,486 |
| 2024-07-08 | Masanovich Matti (SVP, Chief Financial Officer) | Sale | 2,993 | 56.74 | 169,822 |
| 2024-06-04 | Hopson Ricky (Pres. BioProduct Delivery, CoS) | Sale | 1,401 | 54.26 | 76,022 |
| 2024-03-15 | Gunther Scott (SVP, Quality & Reg. Affairs) | Sale | 387 | 56.20 | 21,749 |
| 2023-08-31 | Ryan Michelle R | Buy | 1,000 | 49.98 | 49,980 |
| 2023-08-30 | Greisch John J (Executive Chair) | Buy | 21,000 | 50.24 | 1,055,040 |
| 2023-08-24 | Lickfold Charles (SVP, CIO) | Sale | 190 | 44.72 | 8,496 |
| 2023-08-24 | Hunt Patricia (Pres. Consumer Health Div) | Sale | 106 | 44.77 | 4,745 |
| 2023-08-24 | Hawkeswood Thomas W (Pres. Pharma Prod Delivery Div) | Sale | 147 | 44.72 | 6,573 |
| 2023-08-24 | Carletti Lorenzo (SVP Global Ops Ph & Cons Hlth) | Sale | 216 | 44.71 | 9,657 |
| 2023-08-24 | Hopson Ricky (Pres. Clinical Dev Supply Div) | Sale | 276 | 44.56 | 12,298 |
| 2023-08-24 | Grippo Michael J (SVP, Strategy & Corp. Dev.) | Sale | 390 | 44.50 | 17,355 |
| 2023-08-24 | Pravda Ricardo (Chief Transformation Officer) | Sale | 379 | 44.47 | 16,854 |
| 2023-08-24 | Arnold Jonathan (SVP, CCO & Div. Head BioP Del.) | Sale | 87 | 44.87 | 3,903 |
| 2023-08-24 | Gunther Scott (SVP, Quality & Reg. Affairs) | Sale | 269 | 44.57 | 11,989 |
| 2023-08-24 | Maselli Alessandro (President & CEO) | Sale | 2,071 | 44.83 | 92,842 |
| 2023-08-24 | Gennadios Aristippos (Group Pres. Pharma & Consumer) | Sale | 396 | 44.49 | 17,618 |
| 2023-08-24 | Fasman Steven L (EVP & Chief Admin Officer) | Sale | 817 | 44.65 | 36,479 |
| 2023-08-01 | Lickfold Charles (SVP, CIO) | Sale | 135 | 47.90 | 6,466 |
| 2023-08-01 | Hunt Patricia (Pres. Consumer Health Div) | Sale | 161 | 47.95 | 7,719 |
| 2023-08-01 | Hawkeswood Thomas W (Pres. Pharma Prod Delivery Div) | Sale | 258 | 47.97 | 12,376 |
| 2023-08-01 | Carletti Lorenzo (SVP Global Ops Ph & Cons Hlth) | Sale | 383 | 47.77 | 18,295 |
| 2023-08-01 | Hopson Ricky (Pres. Clinical Dev Supply Div) | Sale | 195 | 47.86 | 9,332 |
| 2023-08-01 | Grippo Michael J (SVP, Strategy & Corp. Dev.) | Sale | 276 | 47.26 | 13,043 |
| 2023-08-01 | Pravda Ricardo (Chief Transformation Officer) | Sale | 269 | 47.14 | 12,680 |
| 2023-08-01 | Arnold Jonathan (SVP, CCO & Div. Head BioP Del.) | Sale | 62 | 47.80 | 2,963 |
| 2023-08-01 | Gunther Scott (SVP, Quality & Reg. Affairs) | Sale | 190 | 47.90 | 9,101 |
| 2023-08-01 | Maselli Alessandro (President & CEO) | Sale | 1,485 | 47.23 | 70,136 |
| 2023-08-01 | Gennadios Aristippos (Group Pres. Pharma & Consumer) | Sale | 281 | 47.23 | 13,270 |
| 2023-08-01 | Fasman Steven L (EVP & Chief Admin Officer) | Sale | 1,637 | 47.24 | 77,331 |
| 2023-05-01 | Boerman Manja (Pres. BioModalities Division) | Sale | 1,446 | 49.86 | 72,097 |
| 2023-05-01 | Gargiulo Mario (SVP, Ops, Biologics Europe) | Sale | 678 | 49.86 | 33,805 |
| 2022-10-31 | Grippo Michael J (SVP, Strategy & Corp. Dev.) | Sale | 2,451 | 65.83 | 161,349 |
| 2022-10-10 | Hawkeswood Thomas W (Pres. Pharma Prod Delivery Div) | Sale | 930 | 77.46 | 72,037 |
| 2022-08-31 | Hopson Ricky (Pres. Clinical Dev Supply Div) | Sale | 4,432 | 89.59 | 397,062 |
| 2022-08-26 | Riley Michael A. (Pres. Bio Product Delivery Div) | Sale | 2,491 | 104.07 | 259,238 |
| 2022-08-26 | Gunther Scott (SVP, Quality & Reg. Affairs) | Sale | 1,639 | 104.07 | 170,570 |
| 2022-08-25 | Riley Michael A. (Pres. Bio Product Delivery Div) | Sale | 1,482 | 103.04 | 152,705 |
| 2022-08-25 | Hunt Patricia (Pres. Consumer Health Div) | Sale | 339 | 103.04 | 34,930 |
| 2022-08-25 | Hawkeswood Thomas W (Pres. Pharma Prod Delivery Div) | Sale | 671 | 103.04 | 69,139 |
| 2022-08-25 | Boerman Manja (Pres. BioModalities Division) | Sale | 3,296 | 103.04 | 339,619 |
| 2022-08-25 | Gargiulo Mario (SVP Global Ops Biologics) | Sale | 1,586 | 103.04 | 163,421 |
| 2022-08-25 | Carletti Lorenzo (SVP Global Ops Ph & Cons Hlth) | Sale | 1,033 | 103.04 | 106,440 |
| 2022-08-25 | Hopson Ricky (Pres. Clinical Dev Supply Div) | Sale | 1,517 | 103.04 | 156,311 |
| 2022-08-25 | Castellano Thomas P (SVP, Chief Financial Officer) | Sale | 1,414 | 103.04 | 145,698 |
| 2022-08-25 | Grippo Michael J (SVP, Strategy & Corp. Dev.) | Sale | 1,670 | 103.04 | 172,076 |
| 2022-08-25 | Pravda Ricardo (SVP & Chief HR Officer) | Sale | 1,747 | 103.04 | 180,010 |
| 2022-08-25 | Schmidt Kay A (SVP, Enterprise Functions) | Sale | 1,321 | 103.04 | 136,115 |
| 2022-08-25 | Arnold Jonathan (SVP & Chief Commercial Ofcr) | Sale | 384 | 103.04 | 39,567 |
| 2022-08-25 | Gunther Scott (SVP, Quality & Reg. Affairs) | Sale | 1,840 | 103.04 | 189,593 |
| 2022-08-25 | Maselli Alessandro (President & CEO) | Sale | 4,646 | 103.04 | 478,723 |
| 2022-08-25 | Gennadios Aristippos (Group Pres. Pharma & Consumer) | Sale | 1,645 | 103.04 | 169,500 |
| 2022-08-25 | Chiminski John R (Executive Chair) | Sale | 38,934 | 103.04 | 4,011,759 |
| 2022-08-25 | Fasman Steven L (EVP & Chief Admin Officer) | Sale | 4,811 | 103.04 | 495,725 |
| 2022-07-27 | Hopson Ricky (Pres, Clinical Dev & Supply) | Sale | 591 | 107.67 | 63,632 |
| 2022-07-27 | Grippo Michael J (SVP, Strategy & Corp. Dev.) | Sale | 388 | 107.67 | 41,775 |
| 2022-07-27 | Gunther Scott (SVP, Quality & Reg. Affairs) | Sale | 394 | 107.67 | 42,421 |
| 2022-07-26 | Gargiulo Mario (SVP Global Ops Biologics) | Sale | 969 | 106.90 | 103,586 |
| 2022-07-26 | Carletti Lorenzo (SVP Global Ops Ph & Cons Hlth) | Sale | 631 | 106.90 | 67,453 |
| 2022-07-26 | Hopson Ricky (Pres, Clinical Dev & Supply) | Sale | 312 | 106.90 | 33,352 |
| 2022-07-26 | Castellano Thomas P (SVP, Chief Financial Officer) | Sale | 347 | 106.90 | 37,094 |
| 2022-07-26 | Grippo Michael J (SVP, Strategy & Corp. Dev.) | Sale | 409 | 106.90 | 43,722 |
| 2022-07-26 | Pravda Ricardo (SVP & Chief HR Officer) | Sale | 427 | 106.90 | 45,646 |
| 2022-07-26 | Schmidt Kay A (SVP, Enterprise Functions) | Sale | 323 | 106.90 | 34,528 |
| 2022-07-26 | Arnold Jonathan (SVP & Chief Commercial Ofcr) | Sale | 94 | 106.90 | 10,048 |
| 2022-07-26 | Gunther Scott (SVP, Quality & Reg. Affairs) | Sale | 450 | 106.90 | 48,105 |
| 2022-07-26 | Maselli Alessandro (President & CEO) | Sale | 816 | 106.90 | 87,230 |
| 2022-07-26 | Gennadios Aristippos (Group Pres. Pharma & Consumer) | Sale | 403 | 106.90 | 43,080 |
| 2022-07-26 | Chiminski John R (Executive Chair) | Sale | 9,691 | 106.90 | 1,035,967 |
| 2022-07-26 | Fasman Steven L (EVP & Chief Admin Officer) | Sale | 2,546 | 106.90 | 272,167 |
| 2022-06-10 | Gargiulo Mario (SVP Global Ops Large Molecule) | Sale | 118 | 106.59 | 12,577 |
| 2022-06-10 | Fasman Steven L (SVP & General Counsel) | Sale | 5,000 | 107.16 | 535,775 |
| 2022-02-06 | Zippelius Peter (Director) | Sale | 487,092 | 102.65 | 49,999,993 |
| 2022-01-31 | Hopson Ricky (VP, Chief Accounting Officer) | Sale | 2,325 | 103.39 | 240,381 |
| 2022-01-21 | Whitlow Ricci S (President, CSS) | Sale | 184 | 102.37 | 18,836 |
| 2022-01-10 | Flynn Karen (Chief Commercial Officer) | Sale | 2,472 | 116.64 | 288,334 |
| 2021-11-30 | Zippelius Peter (Director) | Sale | 3,000,000 | 129.30 | 387,900,000 |
| 2021-11-23 | Lucier Gregory T | Sale | 5,068 | 127.37 | 645,511 |
| 2021-11-01 | Arnold Jonathan (Pres. Oral & Specialty Deliv.) | Sale | 10,672 | 140.02 | 1,494,293 |
| 2021-11-01 | Arnold Jonathan (Pres. Oral & Specialty Deliv.) | Option Ex | 7,559 | 44.27 | 334,621 |
| 2021-10-20 | Castellano Thomas P (SVP, Chief Financial Officer) | Sale | 2,307 | 134.00 | 309,138 |
| 2021-10-14 | Arnold Jonathan (Pres. Oral & Specialty Deliv.) | Sale | 1,661 | 129.41 | 214,950 |
| 2021-10-04 | Schmidt Kay A (SVP, Technical Operations) | Sale | 2,191 | 131.25 | 287,568 |
| 2021-10-04 | Fasman Steven L (SVP & General Counsel) | Sale | 34,714 | 129.79 | 4,505,530 |
| 2021-10-04 | Fasman Steven L (SVP & General Counsel) | Option Ex | 17,259 | 55.73 | 961,930 |
| 2021-10-01 | Grippo Michael J (SVP, Strategy & Corp. Dev.) | Sale | 2,055 | 130.19 | 267,536 |
| 2021-10-01 | Pravda Ricardo (SVP & Chief HR Officer) | Sale | 4,906 | 132.68 | 650,928 |
| 2021-10-01 | Pravda Ricardo (SVP & Chief HR Officer) | Option Ex | 3,818 | 71.52 | 273,063 |
| 2021-10-01 | Chiminski John R (Chair & CEO) | Sale | 152,637 | 130.19 | 19,871,200 |
| 2021-10-01 | Chiminski John R (Chair & CEO) | Option Ex | 75,838 | 38.27 | 2,902,320 |
| 2021-08-27 | Hopson Ricky (VP, Chief Accounting Officer) | Sale | 1,471 | 130.75 | 192,325 |
| 2021-08-27 | Castellano Thomas P (SVP, Chief Financial Officer) | Sale | 2,093 | 130.75 | 273,649 |
| 2021-08-27 | Grippo Michael J (SVP, Strategy & Corp. Dev.) | Sale | 1,698 | 130.75 | 222,005 |
| 2021-08-27 | Pravda Ricardo (SVP & Chief HR Officer) | Sale | 692 | 130.75 | 90,475 |
| 2021-08-27 | Schmidt Kay A (SVP, Technical Operations) | Sale | 825 | 130.75 | 107,864 |
| 2021-08-27 | Arnold Jonathan (Pres. Oral & Specialty Deliv.) | Sale | 452 | 130.75 | 59,096 |
| 2021-08-27 | Gunther Scott (SVP, Quality & Reg. Affairs) | Sale | 4,173 | 130.61 | 545,035 |
| 2021-08-27 | Maselli Alessandro (President & COO) | Sale | 3,743 | 130.75 | 489,378 |
| 2021-08-27 | Gennadios Aristippos (President Softgel & Oral Tech) | Sale | 2,262 | 130.75 | 295,745 |
| 2021-08-27 | Chiminski John R (Chair & CEO) | Sale | 44,488 | 130.76 | 5,817,473 |
| 2021-08-27 | Fasman Steven L (SVP & General Counsel) | Sale | 6,111 | 130.75 | 798,982 |
| 2021-07-26 | Hopson Ricky (VP, Chief Accounting Officer) | Sale | 360 | 113.05 | 40,698 |
| 2021-07-26 | Castellano Thomas P (SVP, Chief Financial Officer) | Sale | 555 | 113.05 | 62,742 |
| 2021-07-26 | Grippo Michael J (SVP, Strategy & Corp. Dev.) | Sale | 451 | 113.05 | 50,985 |
| 2021-07-26 | Pravda Ricardo (SVP & Chief HR Officer) | Sale | 458 | 113.05 | 51,776 |
| 2021-07-26 | Schmidt Kay A (SVP, Technical Operations) | Sale | 547 | 113.05 | 61,838 |
| 2021-07-26 | Arnold Jonathan (Pres. Oral & Specialty Deliv.) | Sale | 120 | 113.05 | 13,566 |
| 2021-07-26 | Gunther Scott (SVP, Quality & Reg. Affairs) | Sale | 1,079 | 113.03 | 121,964 |
| 2021-07-26 | Maselli Alessandro (President & COO) | Sale | 993 | 113.05 | 112,258 |
| 2021-07-26 | Gennadios Aristippos (President Softgel & Oral Tech) | Sale | 465 | 113.05 | 52,568 |
| 2021-07-26 | Chiminski John R (Chair & CEO) | Sale | 11,137 | 113.05 | 1,259,037 |
| 2021-07-26 | Fasman Steven L (SVP & General Counsel) | Sale | 1,549 | 113.05 | 175,114 |
| 2021-07-15 | Fasman Steven L (SVP & General Counsel) | Sale | 4,500 | 110.05 | 495,225 |
| 2021-06-23 | Pravda Ricardo (SVP & Chief HR Officer) | Sale | 2,800 | 110.58 | 309,624 |
| 2021-03-22 | Schmidt Kay A (SVP, Technical Operations) | Sale | 1,400 | 105.77 | 148,078 |
| 2021-03-19 | Chiminski John R (Chair & CEO) | Sale | 183,024 | 106.32 | 19,458,562 |
| 2021-03-19 | Chiminski John R (Chair & CEO) | Option Ex | 183,024 | 42.44 | 7,767,172 |
| 2021-03-18 | Chiminski John R (Chair & CEO) | Sale | 42,220 | 105.16 | 4,439,855 |
| 2021-03-18 | Chiminski John R (Chair & CEO) | Option Ex | 42,220 | 36.02 | 1,520,764 |
| 2021-03-18 | Fasman Steven L (SVP & General Counsel) | Sale | 21,647 | 104.60 | 2,264,276 |
| 2021-03-18 | Fasman Steven L (SVP & General Counsel) | Option Ex | 21,647 | 39.95 | 864,797 |
| 2021-02-16 | Joseph Wetteny (SVP & Chief Financial Officer) | Sale | 5,000 | 124.92 | 624,600 |
| 2021-02-16 | Joseph Wetteny (SVP & Chief Financial Officer) | Option Ex | 5,000 | 49.41 | 247,049 |
| 2021-02-08 | Joseph Wetteny (SVP & Chief Financial Officer) | Sale | 4,604 | 113.73 | 523,612 |
| 2021-01-21 | Whitlow Ricci S (President, CSS) | Sale | 692 | 118.85 | 82,244 |
| 2021-01-11 | Flynn Karen (Pres. Biologics & CCO) | Sale | 2,478 | 112.32 | 278,328 |
| 2021-01-06 | Gunther Scott (SVP, Quality & Reg. Affairs) | Sale | 61 | 104.78 | 6,391 |
| 2021-01-04 | Whitlow Ricci S (President, CSS) | Sale | 83 | 104.42 | 8,666 |
| 2021-01-04 | Grippo Michael J (SVP, Strategy & Corp. Dev.) | Sale | 126 | 104.42 | 13,156 |
| 2021-01-04 | Pravda Ricardo (SVP & Chief HR Officer) | Sale | 78 | 104.42 | 8,144 |
| 2021-01-04 | Schmidt Kay A (SVP, Technical Operations) | Sale | 73 | 104.42 | 7,622 |
| 2021-01-04 | Arnold Jonathan (Pres. Oral & Specialty Deliv.) | Sale | 16 | 104.42 | 1,670 |
| 2021-01-04 | Gunther Scott (SVP, Quality & Reg. Affairs) | Sale | 120 | 104.42 | 12,530 |
| 2021-01-04 | Maselli Alessandro (President & COO) | Sale | 148 | 104.42 | 15,454 |
| 2021-01-04 | Gennadios Aristippos (President Softgel & Oral Tech) | Sale | 110 | 104.42 | 11,486 |
| 2021-01-04 | Flynn Karen (Pres. Biologics & CCO) | Sale | 99 | 104.42 | 10,337 |
| 2021-01-04 | Fasman Steven L (SVP & General Counsel) | Sale | 189 | 104.42 | 19,735 |
| 2021-01-04 | Joseph Wetteny (SVP & Chief Financial Officer) | Sale | 172 | 104.42 | 17,960 |
| 2020-12-21 | Gennadios Aristippos (President Softgel & Oral Tech) | Sale | 13,662 | 102.88 | 1,405,478 |
Insider trading activities including stock purchases, stock sales, and option exercises
of CTLT listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Catalent, Inc. (symbol CTLT,
CIK number 1596783) see
the Securities and Exchange Commission (SEC) website.